Shah Capital Nominates Two Independent Candidates for Novavax

Shah Capital, which owns 6.7% of Novavax, nominates two independent board directors, saying the company’s low share price reflects management failure to capitalize on competitive advantages.

• Nominates Suresh Katta, founder of Saama and CEO of the company for 25 years
• Nominates Venkat Peri, CEO of Quantiva Health, a healthcare company that is putting AI and advanced computational sciences at the intersection of medicine, biology, and healthcare economics
• Shah Capital believes Novavax must improve its marketing strategy, spend efficiently and turn its Matrix-M adjuvant franchise’s inactive pipeline candidates (such as Flu, RSV, and H5N1) into active opportunities through outside capital infusion ...